The clinical performance of imaging and biomarker assessments for non-alcoholic fatty liver disease

Gachon University Gil Medical Center0 个研究点目标入组 75 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•.-Subjects who provided written informed consent
•-Aged 19-70 years
•-those suspected of having NAFLD and belong to one of the followings: who planned to receive liver biopsy or who received liver biopsy for NAFLD within the past 3 months, NAFLD fibrosis score > 0.675, or liver stiffness on FibroScan > 7.5 kPa
•-no congenital or systemic illnesses requiring specific treatment except for NAFLD
•-Those seemed appropriate for study participation on screening tests involving medical history, physical examinations, blood cell test, serum/plasma biochemistry, and urine analysis
•-Healthy adult subjects aged between 19 and 70 years as normal control subjects

•-Aged less than 19 years or more than 70 years
•-Pregnancy
•-Drug abusers
•-Alcohol drink > 30 g/day (about 3 unit/day) in male and > 20 g/day (about 2 unit/day) in female during the last 5 years
•-Contraindications to MRI examination
•-Other liver diseases except for NAFLD
•-Liver cirrhosis with ascites or biliary tract diseases
•-Medications causing fatty liver (e.g., corticosteroids, tamoxifen, amiodarone, methotrexate and others)
•-Other systemic diseases seemed to be inappropriate for study participation
•-Inappropriate for study participation at the discretion of attending physicians

发起方